|Cat #||Size||Price||Quantity Avail.||Save|
|793904||25 µg||350 CHF|
|793906||100 µg||775 CHF|
SARS-CoV-2 is a respiratory virus which causes coronavirus disease 2019 (COVID-19). The coronavirus spike (S) glycoprotein is a class I viral fusion protein on the outer envelope of the virion that plays a critical role in viral infection by recognizing host cell receptors and mediating fusion of the viral and cellular membranes. The S glycoprotein is synthesized as a precursor protein consisting of ~1,300 amino acids that is then cleaved into an amino (N)-terminal S1 subunit (~700 amino acids) and a carboxyl (C)-terminal S2 subunit (~600 amino acids). Three S1/S2 heterodimers assemble to form a trimer spike protruding from the viral envelope. The S1 subunit contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. Triggered by receptor binding, proteolytic processing and/or acidic pH in the cellular compartments, the class I viral fusion protein undergoes a transition from a metastable pre-fusion state to a stable post-fusion state during infection, in which the receptor-binding subunit is cleaved, and the fusion subunit undergoes large-scale conformational rearrangements to expose the hydrophobic fusion peptide, induce the formation of a six-helix bundle, and bring the viral and cellular membranes close for fusion. The trimeric SARS coronavirus (SARS-CoV-2) S glycoprotein consisting of three S1-S2 heterodimers binds the cellular receptor angiotensin-converting enzyme 2 (ACE2) and mediates fusion of the viral and cellular membranes through a pre- to post-fusion conformation transition.Product Details
- SARS-CoV-2 S Protein RBD, amino acid Arg319-Phe541 (Accession # QHD43416.1), with a C-terminal 8-his tag and an Avi-tag was expressed in 293E cells. SARS-CoV-2 S Protein RBD was site-specifically biotinylated by enzyme BirA.
- Molecular Mass
- The 260 amino acid recombinant protein has a predicted molecular mass of approximately 28.9 kD. The DTT-reduced and non-reduced proteins migrate at approximately 35 kD and 30 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Arg.
- > 95%, as determined by Coomassie stained SDS-PAGE
- 0.22 µm filtered protein solution is in PBS, pH 7.2.
- Endotoxin Level
- Less than 0.1 EU per µg protein as determined by the LAL method
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg and larger sizes are lot-specific and bottled at the concentration indicated on the vial (please contact technical support for concentration, or use our Lookup tool if you have a lot number.)
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- When recombinant ACE2-Fc chimera (Cat. No. 793202) is immobilized at 1 µg/mL, biotinylated recombinant SARS-CoV-2 S Protein RBD binds in a dose-dependent manner. The EC50 range for this effect is 8 - 40 ng/mL. HRP Avidin (Cat. No. 405103) was used to detect the binding.
- Application Notes
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at email@example.com.
- Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection
- Lung cells
- Measured by its ability to bind recombinant human ACE2
- Antigen References
- Lu R, et al. 2020. Lancet. 10224:565-74.
- Li F. 2016. Annu Rev Virol. 1:237-61.
- Belouzard S, et al. 2012. Viruses. 6:1011-33.
- Song W, et al. 2018. PLoS Pathog. 8:e1007236
- Shang J, et al. 2020. Nature. 7807:221-224.
- Gene ID
- View information about SARS-CoV-2 S Protein RBD on UniProt.org